VENENUM Biodesign, a Genesis Drug Discovery and Development (GD3) Company, is focused on discovering and advancing innovative new medicines for significant unmet medical needs in key therapeutic areas, including; cancer, inflammation, infectious diseases, metabolic diseases, and women’s health. Our most advanced programs are targeting Clostridium difficile infection (CDI) and Type 2 Diabetes (T2D). Our business model allows us to focus on the creation of high value, innovative small molecule programs against well-validated targets, as well as new targets identified from our own research and to work with partners for clinical and commercial development to bring our products to patients. Our mission is to improve patients’ lives through the discovery of therapeutic compounds against our novel biological targets. Many of our targets involve novel protein-protein or protein-DNA interactions. Others are more conventional target classes e.g., GPCRs and enzymes. Our goal is to advance our discoveries to medicine through partnership with pharmaceutical companies. We utilize state-of-the-art assay development and ultra-high throughput screening (UHTS) against our proprietary 6 million ECLiPS compound collection in conjunction with protein engineering and structural biology, medicinal chemistry, and in vivo models.